Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392932 | 0.83 | EPHX1 (0.30) | — | |
| SCHEMBL18113 | 0.81 | TSHR (0.31) | ALDH1A1TSHR | |
| SCHEMBL30735963 | 0.79 | ATM (0.43) | ALDH1A1TSHR | |
| SCHEMBL20303213 | 0.78 | — | — | |
| SCHEMBL1373738 | 0.78 | TSHR (0.33) | TSHR | |
| SCHEMBL1899483 | 0.77 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL203812 | 0.76 | TSHR (0.33) | ALDH1A1TSHR | |
| SCHEMBL437089 | 0.76 | TSHR (0.33) | ALDH1A1TSHR | |
| SCHEMBL584323 | 0.74 | — | — | |
| SCHEMBL1751456 | 0.72 | ALDH1A1 (0.30) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040156824-A1 | When joined to a delivery vehicle that can target a tumor site, it can increase the subsequent uptake of antineoplastic or tumor imaging agents; can be chemically joined to a monoclonal antibody to form an immunoconjugate | EPSTEIN ALAN L (US) | 2004-08-12 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| US-6737064-B2 | ANTITUMOR AGENTS | THE UNIVERSITY OF SOUTHERN CALIFORNIA | 2004-05-18 | — | — | US | disclosed |
| EP-0931836-B1 | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof | UNIV SOUTHERN CALIFORNIA (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-20020164302-A1 | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof | THE UNIVERSITY OF SOUTHERN CALIFORNIA | 2002-11-07 | — | — | US | disclosed |
| US-6403096-B1 | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof | UNIVERSITY OF SOUTHERN CALIFORNIA | 2002-06-11 | — | — | US | disclosed |
| US-6008319-A | A PERMEABILITY ENHANCING PEPTIDE THAT IS FREE OF CYTOKINE ACTIVITY AND IS JOINED TO A DELIVERY VEHICLE THAT TARGETS TUMORS; THERAPY FOR INCREASING UPTAKE OF ANTITUMOR AGENTS OR TUMOR IMAGING AGENTS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0931836-A1 | Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1999-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | ALDH1A1 844/4885TSHR 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.